Patents by Inventor Jeffrey Albert

Jeffrey Albert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20230183238
    Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.
    Type: Application
    Filed: February 3, 2023
    Publication date: June 15, 2023
    Inventors: Pavel Osten, Kristin K. Baldwin, Robert DeVita, Samuel Desjardins, Jeffrey Albert
  • Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
    Patent number: 11597726
    Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: March 7, 2023
    Assignee: Certego Therapeutics Inc.
    Inventors: Pavel Osten, Kristin K. Baldwin, Robert DeVita, Samuel Desjardins, Jeffrey Albert
  • RING DEUTERATED GABOXADOL AND ITS USE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS
    Publication number: 20220127261
    Abstract: Ring deuterated gaboxadol is provided. The ring deuterated gaboxadol is useful in the treatment of psychiatric disorders and is more effective than non-deuterated gaboxadol in such treatments. Deuterated gaboxadol is useful in combinations with other compounds to provide additive and synergistic effects for patient therapies. In a specific embodiment, the deuterated gaboxadol is d6-gaboxadol.
    Type: Application
    Filed: May 20, 2021
    Publication date: April 28, 2022
    Inventors: Pavel Osten, Kristin K. Baldwin, Robert DeVita, Sam Desjardins, Jeffrey Albert
  • Alkylsulphonamide quinolines
    Patent number: 8071621
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: October 9, 2009
    Date of Patent: December 6, 2011
    Assignee: AstraZeneca AB
    Inventors: Thomas Simpson, James Kang, Jeffrey Albert, Cristobal Alhambra, Gerard Koether, James Woods, Yan Li
  • Alkylsulphonamide Quinolines
    Publication number: 20100029717
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: October 9, 2009
    Publication date: February 4, 2010
    Inventors: Thomas Simpson, James Kang, Jeffrey Albert, Cristobal Alhambra, Gerard Koether, James Woods, Yan Li
  • Novel 2-Aminopyrimidinone Derivatives And Their Use
    Publication number: 20090215801
    Abstract: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: August 27, 2009
    Applicant: ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD
    Inventors: Jeffrey Albert, Donald Andisik, Phil Edwards, Mark Sylvester
  • Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia
    Publication number: 20090176850
    Abstract: This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 9, 2009
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Jeffrey Albert, James Arnold, Gianni Chessari, Miles Stuart Congreve, Phil Edwards, Christopher Murray, Sahil Patel
  • Amide Substituted Quinolines
    Publication number: 20090054445
    Abstract: Compounds of Formula I wherein R1, A, R2, n, R3, m, R4, R5 and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: January 25, 2007
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey Albert, Cristobal Alhambra, James Kang, Gerard Koether, Yan Li, Thomas Simpson, James Woods
  • Novel 2-Aminopyrimidinone Or 2-Aminopyridinone Derivatives and Their Use
    Publication number: 20080318985
    Abstract: This invention relates to novel compounds having the structural formula Ia or Ib below: (Ia); (Ib) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: December 25, 2008
    Applicants: AstraZeneca AB, Astex Therapeutics Limited
    Inventors: Jeffrey Albert, Phil Edwards, James Empfield
  • Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies
    Publication number: 20080293709
    Abstract: This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: November 27, 2008
    Applicant: AstraZeneca AB
    Inventors: Jeffrey Albert, Gianni Chessari, Miles Stuart Congreve, Phil Edwards, Christopher Murray, Sahil Patel, Mark Sylvester
  • Alkylsulphonamide Quinolines
    Publication number: 20080293765
    Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: December 11, 2006
    Publication date: November 27, 2008
    Inventors: Jeffrey Albert, Cristobal Alhambra, James Kang, Gerard Koether, Thomas Simpson, James Woods, Yan Li
  • Novel 2-Aminopyrimidine or 2-Aminiopyridinone Derivatives and Their Use
    Publication number: 20080255167
    Abstract: This invention relates to novel compounds having the structural formula I below and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: October 16, 2008
    Inventors: Jeffrey Albert, Gianni Chessari, Phil Edwards
  • Novel 2-Aminopyrimidinone Derivatives And Their Use
    Publication number: 20080255164
    Abstract: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: November 13, 2006
    Publication date: October 16, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Jeffrey Albert, Donald Andisik, Phil Edwards, Mark Sylvester
  • Alkylsulphonamide Quinolines
    Publication number: 20080021062
    Abstract: Compounds of Formula II wherein R1, A, R2, R3, R4, R5, R8, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: December 11, 2006
    Publication date: January 24, 2008
    Inventors: Thomas Simpson, James Kang, Jeffrey Albert, Cristobal Alhambra, Gerard Koether, James Woods, Yan Li
  • New neurokinin antagonists for use as medicaments
    Publication number: 20070021406
    Abstract: The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1, X2, Y, Z, and n are as defined herein), which are useful, for example, for antagonizing the pharmacological actions of the neurokinin 1 (NK1) receptor.
    Type: Application
    Filed: January 24, 2005
    Publication date: January 25, 2007
    Inventors: Jeffrey Albert, Peter Bernstein, Cyrus Ohnmacht, Keith Russell, Ashokkumar Shenvi